Recent research has uncovered an important mechanism related to bone strengthening in the body, which could offer potential treatments for osteoporosis, a condition that weakens bones.
Conducted by scientists from the University of Leipzig in Germany and Shandong University in China, the 2025 study discovered that the cell receptor GPR133 (known also as ADGRD1) plays a crucial role in maintaining bone density through the action of osteoblast cells, which are responsible for bone formation.
Previous studies had already established a connection between variations in the GPR133 gene and bone density. This prompted researchers to investigate the specific protein produced by this gene.
The team performed experiments with mice, manipulating the GPR133 gene’s presence: either by completely removing it or activating it with a chemical known as AP503.
Mice without the GPR133 gene exhibited weak bones, showing symptoms that closely resemble those of osteoporosis. In contrast, when the receptor was present and activated by AP503, the mice demonstrated an improvement in bone production and overall strength.
“By using AP503, which was identified through a computer-assisted screening as a GPR133 stimulator, we significantly boosted bone strength in both healthy and osteoporotic mice,” remarked Ines Liebscher, a biochemist at the University of Leipzig, upon sharing these exciting findings last year.
In this context, AP503 acts like a biological switch that gets osteoblasts to work harder. The researchers also showed that it could complement exercise efforts to further enhance bone strength.
Finding that the GPR133 receptor is vital for maintaining robust bone health in mice is a significant insight. While the study was conducted using an animal model, it’s likely that the fundamental mechanisms are similar in humans.
Liebscher added that impairment of this receptor due to genetic changes can lead to early signs of bone density loss in mice, mirroring aspects of osteoporosis seen in humans.
Osteoporosis is a serious issue affecting millions globally. Currently available treatments can slow its progression, but no existing methods can fully reverse or cure the disease. Additionally, these treatments may pose risks of side effects or lose effectiveness over time.
There are multiple factors influencing bone strength, which offers researchers a breadth of avenues for developing strategies that prevent osteoporosis and promote healthier aging.
In 2024, a research team developed a blood-based implant that leverages this mechanism for repairing broken bones. This innovation capitalizes on the body’s natural healing processes, where blood clots are part of repairing injuries.
The research team dubbed this implant a “biocooperative regenerative” material, as it uses synthetic peptides to enhance the functionality of blood clots. In tests with rats, this gel-like substance demonstrated effectiveness in restoring bone damage. If adapted for human use, it could significantly enhance natural healing.
Biomedical engineer Cosimo Ligorio from the University of Nottingham expressed excitement about the potential of transforming blood into highly regenerative implants, noting that blood is relatively easy to obtain in large volumes from patients.
Research has continually aimed to tap into the body’s inherent repair mechanisms for better medical solutions, whether by boosting immunity or enhancing natural materials with synthetic elements.
Our bodies have impressive capabilities to heal injuries, but these processes can sometimes be overwhelmed, and, understandably, they tend to diminish with age.
Another recent finding in this research area involves a new hormone in female mice that promotes the growth of very strong and dense bones. In a 2024 study, scientists from the University of California, San Francisco identified a hormone called maternal brain hormone (MBH) that appears to boost bone strength—and this was seen in both male and female mice.
“This hormone leads to a significant increase in bone strength,” explained Thomas Ambrosi, a stem cell biologist, at that time. “We’ve never achieved this kind of healing outcome with any other approach.”
While many breakthroughs have been observed only in animals so far, the prospects for future medications aimed at strengthening bones look very encouraging.
The authors of the 2025 study anticipate that future treatments might not only fortify healthy bones but also restore strength to compromised bones in cases like osteoporosis often induced during menopause.
As Juliane Lehmann, a molecular biologist from the University of Leipzig, commented, the recent findings about the receptor further highlight its potential for medical applications in an aging demographic.
The research was detailed in Signal Transduction and Targeted Therapy.
